Part of the PREDiCT series, the 7th Annual Tumor Models Boston summit continues to act as the focal point for preclinical and translational scientists looking to improve their early stage candidate decision making. Returning for its 7th year, we will be bringing together model developers and pharmaceutical scientists actively seeking to explore how classical and emerging models are evolving strategies supporting efficacy determination, biomarker discovery and combination therapies to the clinic with more confidence.
This year, over 39 Preclinical & Translational Oncology Heads, each pioneering the further development and application of experimental models, will be sharing the latest insights on the impact of their work. Joining them will be 100+ senior level scientists from pharma, model developer and academic labs set to review the comparative cost-per-data point of next generation models alongside classical model-systems.
Tackling core challenges at heart of oncology & IO R&D, key themes to be explored at the 7th Annual PREDiCT: Tumor Models Boston summit include: